NanoViricides, Inc. has retained Id3A, LLC as the architect for its lab and cGMP pilot production facility. The facility will be built by renovating an existing 18,000-sq.-ft. light manufacturing plant in Shelton, CT. The cGMP pilot plant is being designed for the production of sufficient quantities of the drug needed for human clinical trials for each of the various nanoviricides drug candidates entering trials.
 
Kathyann Cowles, AIA, will serve as the principal architect for the project. Id3A will be responsible for the overall facility architecture, including integration of a separately constructed clean room suite for cGMP production. Ms. Cowles will join Andrew Hahn and Phil Mader of MPH Engineering, LLC on the architecture, design and construction management team.
 
Prior to founding Id3A, Ms. Cowles worked on a variety of projects in the Pharma, Medical, Academic, and Science sectors, including Chemistry and Biology (BL4) Lab Renovations, an MRI Suite, and CADD and SATT Lab projects at Bristol-Myers-Squibb in Wallingford, CT.
 
“Ms. Cowles has a unique ability to work with clients in meeting complex and detailed requirements,” said Anil R. Diwan, Ph.D., president of the company, adding, “This is critically important for our challenging project that specifies not only state-of-the-art facility requirements, but also cost sensitivity, space efficiency, and a high degree of energy efficiency.”